153 related articles for article (PubMed ID: 27650015)
1. [Paget's disease of bone: diagnosis and treatment].
Winter EM; Hamdy NA; de Jongh RT; Eekhoff EM; Zillikens MC; Appelman-Dijkstra NM
Ned Tijdschr Geneeskd; 2016; 160():D254. PubMed ID: 27650015
[TBL] [Abstract][Full Text] [Related]
2. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
3. Persistent effect of zoledronic acid in Paget's disease.
Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid for treatment of Paget's disease of bone.
Devogelaer JP; Manicourt DH
Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
Keating GM; Scott LJ
Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of Paget's disease of bone: importance of the zoledronic acid].
Griz L; Colares V; Bandeira F
Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):845-51. PubMed ID: 17160207
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid for Paget's disease of bone.
Maricic M
Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of Paget's disease of bone with zoledronic acid].
Body JJ; Sternon J
Rev Med Brux; 2005; 26(6):513-7. PubMed ID: 16454155
[TBL] [Abstract][Full Text] [Related]
9. The use of zoledronic acid for Paget's disease of bone.
Maricic M
Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
[TBL] [Abstract][Full Text] [Related]
10. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
Conesa Mateos A; Rotés Sala D; Almirall Bernabé M; Carbonell Abelló J
Med Clin (Barc); 2006 Oct; 127(16):635-6. PubMed ID: 17145033
[No Abstract] [Full Text] [Related]
11. [Therapy of Paget's disease].
Kurth AA
Orthopade; 2007 Feb; 36(2):118, 120-3. PubMed ID: 17252256
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
Reid IR; Maslowski K
Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
[TBL] [Abstract][Full Text] [Related]
13. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
Gennari L; Merlotti D; Mossetti G; Rendina D; De Paola V; Martini G; Nuti R
Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402
[TBL] [Abstract][Full Text] [Related]
14. Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1.
Polyzos SA; Anastasilakis AD; Litsas I; Sapranidis M; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Zafeiriadou E; Papatheodorou A; Terpos E
J Clin Densitom; 2010; 13(2):190-6. PubMed ID: 20347367
[TBL] [Abstract][Full Text] [Related]
15. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
Avramidis A; Polyzos SA; Moralidis E; Arsos G; Efstathiadou Z; Karakatsanis K; Grollios G; Kita M
J Bone Miner Metab; 2008; 26(6):635-41. PubMed ID: 18979164
[TBL] [Abstract][Full Text] [Related]
16. [Paget's disease: case report].
Wegierska M; Ignaczak P; Zalewska J; Jeka S
Ann Acad Med Stetin; 2011; 57(3):64-9; discussion 69. PubMed ID: 23383549
[TBL] [Abstract][Full Text] [Related]
17. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Krane SM
Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
[No Abstract] [Full Text] [Related]
18. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
19. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
20. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
Polyzos SA; Anastasilakis AD; Anagnostis P; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
Endokrynol Pol; 2012; 63(4):312-5. PubMed ID: 22933168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
